177 related articles for article (PubMed ID: 31216225)
1. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Sinisalo M
Hum Vaccin Immunother; 2019; 15(12):2910-2913. PubMed ID: 31216225
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
Thisyakorn U; Chokephaibulkit K; Kosalaraksa P; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S
Hum Vaccin Immunother; 2014; 10(7):1859-65. PubMed ID: 25424793
[TBL] [Abstract][Full Text] [Related]
3. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
4. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
Pasiarski M; Rolinski J; Grywalska E; Stelmach-Goldys A; Korona-Glowniak I; Gozdz S; Hus I; Malm A
PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
[TBL] [Abstract][Full Text] [Related]
5. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
6. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.
Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Itälä-Remes M; Sinisalo M
Hum Vaccin Immunother; 2018 Jun; 14(6):1471-1474. PubMed ID: 29420116
[TBL] [Abstract][Full Text] [Related]
7. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
9. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
[TBL] [Abstract][Full Text] [Related]
10. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
13. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
15. Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease.
Ingels HAS; Kantsø B; Slotved HC
BMC Infect Dis; 2018 Aug; 18(1):366. PubMed ID: 30081840
[TBL] [Abstract][Full Text] [Related]
16. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
17. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
van den Biggelaar AHJ; Richmond PC; Fuery A; Anderson D; Opa C; Saleu G; Lai M; Francis JP; Alpers MP; Pomat WS; Lehmann D
PLoS One; 2017; 12(10):e0185877. PubMed ID: 29028802
[TBL] [Abstract][Full Text] [Related]
19. Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era.
Mohamed OE; Williams L; Wong GK; Hayes M; Townsend K; Harding S; Huissoon AP
J Immunol Methods; 2020 Nov; 486():112846. PubMed ID: 32882318
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
